MissionThe mission of the 2012 ASPIRE Awards in Antibacterial Research is to advance the medical knowledge to better understand disease pathogenesis, risk factors, host response and treatment outcomes of linezolid in complex adult patients within approved indications.
BackgroundConsiderable clinical trial data exists for linezolid in a variety of patients with known infections. However, most of this information is from controlled clinical trials and patients with certain disease complexities are underrepresented.
Request for ProposalsPfizer invites investigators to apply for the 2012 ASPIRE Awards in Antibacterial Research through submission of innovative clinical research proposals that evaluate linezolid’s role in the treatment of infections in complex adult patients within approved indications.
2012 Research TopicNarrow Spectrum Antibiotics for the Treatment of MRSA: Clinical Evaluation in Complex Adult Patients
Research RequirementsAn applicant should have a strong academic career interest within the areas of focus and should consider the following components when developing their research proposals:
A. Clinical evaluations of linezolid within the following disease states:
- Nosocomial Pneumonia (e.g. HAP, VAP, HCAP)
- Skin and soft tissue infection (e.g. surgical site infection, wound, complicated cellulitis)
- Diabetic foot infection without osteomyelitis
- Renal insufficiency
- Pulmonary dysfunction (e.g. COPD)
- Peripheral Vascular Disease
- Morbid obesity
- Older adults stratified by age (e.g. 60-70 years, 70-80 years, > 80 years)
- Adults stratified by age (e.g. 18-35 years, 36-55 years, 56-72 years, > 72)
- Critically ill
- Host immune response
- Rate of resolution of signs/symptoms of infection
- General education and / or training
- Public health
- Support for ongoing clinical programs that are part of an organization’s routine operations
- Proposals that do not evaluate linezolid
Research ExpectationsWithin the specified patient populations with infection types of interest, investigators are expected to:
- Generate exploratory clinical data in adult patients with infection types of interest receiving linezolid to better understand disease pathogenesis, risk factors, host response and treatment outcomes
- Be able to complete the research in 12 months
- Present and/or publish the results of the study
Investigators may consider evaluating additional clinical measures (e.g. length of stay, readmission, ventilator days, etc.). However, proposals seeking to financially quantify outcomes are outside the scope of the program. See FAQ’s for guidance.
Available AwardsPfizer is funding awards from $50,000 to a maximum of $100,000* (including direct costs, institutional overhead costs, and indirect costs) each for one year to conduct research generating data that will lead to a better understanding of the safety and efficacy of linezolid in complex patients within approved indications.
*Please note that study budgets will be evaluated separately to ensure the requested funding is commensurate with the work proposed.